NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)
Company is using its Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for patients with relapsed and/or refractory hematologic malignancies